摘要
呼吸道合胞病毒(RSV)是一种核糖核酸(RNA)病毒,该病毒经空气飞沫和密切接触传播,属副黏液病毒科,是引起婴儿、老年人以及免疫功能低下者急性下呼吸道感染的主要病原体。虽然一直致力于研究预防和治疗RSV的药物,但在RSV感染患者中,仍有很高的医疗需要未得到满足,目前尚无专门的抗病毒治疗方法。唯一被批准的用于预防和治疗RSV的药物是帕利珠和利巴韦林,但前者必须预防性使用,且主要用于高危患儿;后者疗效不显著,甚至有的患儿出现气道痉挛的情况。因此,急需提出新的预防和治疗RSV的方法。近年来,中药在抗RSV方面显示出了良好的效果,并且中药的毒副作用小、较少产生耐药性、具有广谱抗病毒等优势;生物药物和化学药物也在不断开发新的抗RSV的药物,一些新的药物已经显示出了较好的疗效,延长了半衰期并降低了成本,如融合抑制剂、单克隆抗体等。本文从中药、生物药物和化学药物方面综述了抗RSV的药物研究进展,为抗RSV的新药研发和制定新的治疗策略奠定基础。
Respiratory syncytial virus(RSV)is an RNA virus,which belongs to the paramyxoviridae family,and is transmitted by air droplets and close contact and the main pathogen causing acute lower respiratory tract infection in infants,the elderly and immunocompromised individuals.Although there have been studies on the prevention and treatment of RSV drugs and RSV infection in patients,many medical demands have not been met.And there is no specific antiviral therapy.The only two drugs approved to be applied in RSV prevention and treatment are perizol and ribavirin.However,the former must be used prophylactically,and primarily in high-risk children,while the latter is less effective,and some children even suffer from airway spasm.Therefore,it is urgent to propose new methods for prevention and treatment of RSV.In recent years,traditional Chinese medicine(TCM)has shown a good anti-RSV effect,with a fewer side effects,less resistance to drugs and broad-spectrum antiviral advantage.There are also newly developed biological and chemical anti-RSV drugs.Some new drugs have shown a good efficacy,with an extended half-life and reduced costs,such as fusion inhibitors,monoclonal antibodies.This paper reviews the research progress of anti-RSV drugs in the aspects of TCM,biological drug and chemical drugs,laying a foundation for the development of new anti-RSV drugs and the formulation of new therapeutic strategies.
作者
王鑫瑞
张天锡
王德民
王红
杨敏
李峰
冯帅
WANG Xin-rui;ZHANG Tian-xi;WANG De-min;WANG Hong;YANG Min;LI Feng;FENG Shuai(Shandong University of Traditional Chinese Medicine,Ji'nan 250355,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2020年第5期241-250,共10页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家“重大新药创制”科技重大专项(2017ZX09301058).
关键词
中药单体
单味中药
中药复方
生物药物
化学药物
呼吸道合胞病毒
monomer of traditional Chinese herb
single traditional Chinese herb
Chinese herbal compound presription
biological drug
chemical drugs
respiratory syncytial virus
作者简介
第一作者:王鑫瑞,硕士,从事中药质量控制与资源研究,E-mail:17862954503@163.com;通信作者:李峰,博士,教授,从事中药质量控制与资源研究,E-mail:13969141796@163.com;通信作者:冯帅,博士,讲师,从事中药质量控制与资源开发,E-mail:fengshuaihappy@163.com
